|  | Bone metasta ses-free survival | Pvalue | |
---|---|---|---|---|
 |  | ≤ 1 year | > 1 year | χ2 test Logistic |
Gender | Female | 2 (6.7%) | 2 (6.7%) | 1.00 |
 | Male | 16 (53.3%) | 10 (33.3%) |  |
Age | ≤50 | 11 (36.7%) | 6 (20.0%) | 0.711 |
 | >50 | 7 (23.3%) | 6 (20.0%) |  |
HbsAg | - | 3 (10.0%) | 0 (0%) | 0.255 |
 | + | 15 (50.0%) | 12 (40.0%) |  |
Γ-GT | ≤75 | 8 (26.7%) | 6 (20.0%) | 1.00 |
 | >75 | 10 (33.3%) | 6 (20.0%) |  |
AFP | ≤400 | 9 (30.0%) | 7 (23.3%) | 0.722 |
 | >400 | 9 (30.0%) | 5 (16.7%) |  |
Child-Pugh Classification | A | 14 (46.7%) | 8 (26.7%) | 0.678 |
 | B | 4 (13.3%) | 4 (13.3%) |  |
Shanghai criteria | Exceeding | 11 (36.7%) | 3 (10.0%) | 0.072 0.053 |
 | Within | 7 (23.3%) | 9 (30.0%) |  |
UCSF | Exceeding | 13 (43.3%) | 5 (16.7%) | 0.136 |
 | Within | 5 (16.7%) | 7 (23.3%) |  |
Milan | Exceeding | 13 (43.3%) | 7 (23.3%) | 0.694 |
 | Within | 5 (16.7%) | 5 (16.7%) |  |
Interval between diagnosis of HCC and LT | ≤0.5 year | 8 (26.7%) | 9 (30.0%) | 0.141 |
 | >0.5 year | 10 (33.3%) | 3 (10.0%) |  |
Soft-tissue extension | Absent | 16 (53.3%) | 5 (16.7%) | 0.013 0.052 |
 | Present | 2 (6.7%) | 7 (23.3%) |  |
No. of bone metastases | Solitary | 6 (20.0%) | 8 (26.7%) | 0.135 |
 | ≥2 sites | 12 (40.0%) | 4 (13.3%) |  |
Intrahepatic tumor control | uncontrolled | 9 (30.0%) | 1 (3.3%) | 0.045 0.018 |
 | Well-controlled | 9 (30.0%) | 11 (36.7%) |  |
Concurrent distant metastases | Absent | 10 (33.3%) | 5 (16.7%) | 0.710 |
 | Present | 8 (26.7%) | 7 (23.3%) |  |